Immunologic Testing for COVID-19

The rapid and cost-effective production of conventional monoclonal antibodies (mAbs) for clinical trials has contributed toward their wide adoption. As the number of next-generation antibody-based candidates with modified or absent Fc domains increases, biomanufacturers face a need to establish alternative affinity purification technologies.

Over the past two decades, monoclonal antibodies (mAbs) have been one of the most dominant segments of the biotherapeutics market. Ensuring mAbs’ safety and efficacy is vital but is made complicated by the fact that antibodies can have a tendency to aggregate during production, decreasing efficacy and increasing the risk of immunogenicity.

Protein purification can be a challenging process. Since proteins are expressed in biological systems such as cells, the protein must be purified from a complex mixture. Generic column-based purification procedures exploiting differences in protein size and charge, tend to give imperfect results.